• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Putting Data into Practice: A Review of Phase III and Long-Term Efficacy Data for Bimekizumab for Plaque Psoriasis.将数据应用于实践：优时比单抗治疗斑块状银屑病的III期及长期疗效数据综述
J Clin Aesthet Dermatol. 2024 May;17(5 Suppl 2):S7-S10.
2
Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge.用于治疗银屑病的比美吉珠单抗：当前知识综述
Psoriasis (Auckl). 2022 Jun 8;12:127-137. doi: 10.2147/PTT.S367744. eCollection 2022.
3
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.比美克珠单抗治疗中重度斑块状银屑病患者的安全性：来自 2 期和 3 期随机临床试验的汇总结果。
JAMA Dermatol. 2022 Jul 1;158(7):735-744. doi: 10.1001/jamadermatol.2022.1185.
4
Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and Perspectives.比美吉珠单抗治疗斑块状银屑病：聚焦患者选择与展望
Patient Prefer Adherence. 2023 Jun 30;17:1541-1549. doi: 10.2147/PPA.S350760. eCollection 2023.
5
Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation.中度至重度斑块状银屑病患者的比美吉珠单抗治疗：药物安全性评估
Expert Opin Drug Saf. 2023 Jan-Jun;22(5):355-362. doi: 10.1080/14740338.2023.2218086. Epub 2023 Jun 19.
6
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.比美吉珠单抗治疗中重度斑块型银屑病的疗效和安全性（BE READY）：一项多中心、双盲、安慰剂对照、随机撤药阶段 3 期临床试验。
Lancet. 2021 Feb 6;397(10273):475-486. doi: 10.1016/S0140-6736(21)00126-4.
7
Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study.比美吉珠单抗治疗中度至重度斑块型银屑病：来自一项 IIa 期、随机、双盲、多中心研究的疗效、安全性、药代动力学、药效学和转录组学。
Br J Dermatol. 2022 Apr;186(4):652-663. doi: 10.1111/bjd.20827. Epub 2021 Dec 27.
8
Review of bimekizumab in the treatment of psoriasis.中文标题：比美吉单抗治疗银屑病的研究进展。
Hum Vaccin Immunother. 2022 Nov 30;18(6):2119767. doi: 10.1080/21645515.2022.2119767. Epub 2022 Sep 12.
9
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.在中重度斑块型银屑病患者中，经过 2 年的比美吉珠单抗治疗的安全性和有效性：来自 BE SURE 随机对照试验和 BE BRIGHT 试验开放标签扩展的长期结果。
Br J Dermatol. 2023 Jan 23;188(1):22-31. doi: 10.1093/bjd/ljac021.
10
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.比美吉珠单抗与乌司奴单抗治疗中度至重度斑块型银屑病（BE VIVID）：一项为期 52 周、多中心、双盲、活性对照和安慰剂对照的 3 期临床试验的疗效和安全性。
Lancet. 2021 Feb 6;397(10273):487-498. doi: 10.1016/S0140-6736(21)00125-2.

本文引用的文献

1
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials.布罗达单抗治疗中重度斑块状银屑病的安全性：来自随机III期试验长达3年治疗的汇总数据
Br J Dermatol. 2024 Mar 15;190(4):477-485. doi: 10.1093/bjd/ljad429.
2
Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial.在中重度斑块型银屑病患者中，比美吉珠单抗维持治疗应答 3 年：来自 BE BRIGHT 开放性扩展试验的结果。
Br J Dermatol. 2023 May 24;188(6):749-759. doi: 10.1093/bjd/ljad035.
3
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.在从阿达木单抗、乌司奴单抗或司库奇尤单抗转换治疗的中重度斑块型银屑病患者中，比美吉珠单抗的疗效和安全性：III 期/IIIb 期试验结果。
Br J Dermatol. 2023 Feb 22;188(3):330-340. doi: 10.1093/bjd/ljac089.
4
Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis.比美吉珠单抗及其他生物制剂治疗中度至重度斑块状银屑病的疗效：系统文献综述与网状Meta分析
Dermatol Ther (Heidelb). 2022 Aug;12(8):1777-1792. doi: 10.1007/s13555-022-00760-8. Epub 2022 Jul 7.
5
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.比美克珠单抗治疗中重度斑块状银屑病患者的安全性：来自 2 期和 3 期随机临床试验的汇总结果。
JAMA Dermatol. 2022 Jul 1;158(7):735-744. doi: 10.1001/jamadermatol.2022.1185.
6
Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources.与白细胞介素-17抑制剂相关的念珠菌病风险：一项来自多个独立来源的真实世界观察性研究。
Lancet Reg Health Eur. 2021 Nov 22;13:100266. doi: 10.1016/j.lanepe.2021.100266. eCollection 2022 Feb.
7
Bimekizumab versus Secukinumab in Plaque Psoriasis.比美吉珠单抗与司库奇尤单抗治疗斑块状银屑病的疗效比较。
N Engl J Med. 2021 Jul 8;385(2):142-152. doi: 10.1056/NEJMoa2102383. Epub 2021 Apr 23.
8
Bimekizumab versus Adalimumab in Plaque Psoriasis.比美吉单抗与阿达木单抗治疗斑块状银屑病的疗效比较。
N Engl J Med. 2021 Jul 8;385(2):130-141. doi: 10.1056/NEJMoa2102388. Epub 2021 Apr 23.
9
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.比美吉珠单抗与乌司奴单抗治疗中度至重度斑块型银屑病（BE VIVID）：一项为期 52 周、多中心、双盲、活性对照和安慰剂对照的 3 期临床试验的疗效和安全性。
Lancet. 2021 Feb 6;397(10273):487-498. doi: 10.1016/S0140-6736(21)00125-2.
10
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.比美吉珠单抗治疗中重度斑块型银屑病的疗效和安全性（BE READY）：一项多中心、双盲、安慰剂对照、随机撤药阶段 3 期临床试验。
Lancet. 2021 Feb 6;397(10273):475-486. doi: 10.1016/S0140-6736(21)00126-4.

Putting Data into Practice: A Review of Phase III and Long-Term Efficacy Data for Bimekizumab for Plaque Psoriasis.

作者信息

Beer Jacob, Hermak Sarah, Noor Omar

机构信息

Dr. Beer and Ms. Hermak are with the Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery at the University of Miami in Miami, Florida.

Dr. Noor is a board-certified dermatologist practicing in New York and New Jersey and is the co-owner of Rao Dermatology.

出版信息

J Clin Aesthet Dermatol. 2024 May;17(5 Suppl 2):S7-S10.

PMID:38726208
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11078528/
Abstract
摘要